Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Erenumab
Treatment for Migraine
Typical Dosage: 70mg or 140mg subcutaneous monthly
Effectiveness
85%
Safety Score
65%
Clinical Trials
64
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
70mg or 140mg subcutaneous monthly
Time to Effect
1-4 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$9,000
Monitoring:$200
Side Effect Mgmt:$150
Total Annual:$9,350
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$20,778
Cost per Remission
$62,333
Comparison vs Standard Oral Prophylactics
Cost Difference
+$8,500/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Erenumab Outcomes
for Migraine
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+45%
Remission Rate
+15%
Common Side Effects
Constipation
+15%
Muscle cramps/spasms
+8%
Injection site reaction
+6%
Hypertension (rare)
+1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Erenumab in Migraine
Aimovig Pregnancy Exposure Registry
NCT06150781RECRUITING
2.84K participants
OBSERVATIONAL
Durham, United States
Started: Jan 27, 2021
Completed Clinical Trials
14 completed trials for Erenumab in Migraine
Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data
NCT05177406COMPLETED
1.84K participants
OBSERVATIONAL
East Hanover, United States
Started: Aug 31, 2020
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
NCT04084314COMPLETEDPHASE4
701 participants
INTERVENTIONAL
Stuttgart, Germany +74 more
Started: Sep 30, 2019
Imaging the Migraine Brain Pre- and Post-Erenumab
NCT03773562COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Scottsdale, United States
Started: Mar 25, 2019
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
NCT02630459COMPLETEDPHASE2
475 participants
INTERVENTIONAL
Kamogawa-shi, Japan +43 more
Started: Jan 6, 2016
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
NCT04825678COMPLETEDPHASE4
240 participants
INTERVENTIONAL
Huntsville, United States +41 more
Started: Jun 11, 2021
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
NCT05375097COMPLETED
162 participants
OBSERVATIONAL
East Hanover, United States
Started: Jul 3, 2020
Biomarker and Genetic Predictors of Erenumab Treatment Response
NCT04265755COMPLETEDPHASE4
1.41K participants
INTERVENTIONAL
Glostrup Municipality, Denmark +1 more
Started: Oct 26, 2020
Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19
NCT05052008COMPLETED
90 participants
OBSERVATIONAL
Al Fayyum, Egypt
Started: Aug 15, 2020
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
NCT01952574COMPLETEDPHASE2
483 participants
INTERVENTIONAL
Phoenix, United States +65 more
Started: Aug 6, 2013
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
NCT03977649COMPLETEDPHASE4
62 participants
INTERVENTIONAL
Milan, Italy +4 more
Started: Jul 30, 2019
A Controlled Trial of Erenumab in Migraine Prevention
NCT03812224COMPLETEDPHASE3
261 participants
INTERVENTIONAL
Matsuyama, Japan +40 more
Started: Apr 12, 2019
Efficacy of Erenumab on Functional Impact of Migraine
NCT04465357COMPLETEDPHASE4
55 participants
INTERVENTIONAL
Chicago, United States +2 more
Started: Oct 22, 2020
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
NCT04252742COMPLETEDPHASE4
512 participants
INTERVENTIONAL
Long Beach, United States +90 more
Started: Sep 15, 2020
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
NCT03867201COMPLETEDPHASE3
557 participants
INTERVENTIONAL
Beijing, China +62 more
Started: Aug 26, 2019
Showing 20 of 65 total trials